» Articles » PMID: 17076869

Longitudinal Metric Properties of Disability Rating Scales for Parkinson's Disease

Overview
Journal Value Health
Publisher Elsevier
Date 2006 Nov 2
PMID 17076869
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: This study analyzes the longitudinal metric attributes of three Parkinson's disease (PD) disability scales, taking Hoehn and Yahr (HY) staging as the reference measure of PD progression.

Methods: A sample of 87 PD patients was assessed during regular medical visits, using the HY, the Unified Parkinson's Disease Rating Scale--Activities of Daily Living Section (UPDRS-ADL), the Schwab and England Scale (SES), and the Intermediate Scale for Assessment of PD (ISAPD), across a follow-up period of 2.6 +/- 1.0 years.

Results: The following cross-sectional attributes were analyzed, at baseline and again on conclusion of the study: floor and ceiling effects, convergent validity, reliability, and standard error of measurement, all of which were found to be adequate. Longitudinal reproducibility values (intraclass correlation coefficient) were 0.81 (ISAPD) to 0.84 (UPDRS-ADL). Insofar as longitudinal validity was concerned, the change scores of the three disability scales correlated significantly with the HY change score, absolute value r = 0.33 to 0.45, P < 0.003. Slightly lower values were found when taking the annual rate of change, absolute value r = 0.20 to 0.36. The three scales were acceptable, even though there were small differences among them. The "minimal clinically important difference" proposed for these scales is: SES, -6; UPDRS-ADL, +2; ISAPD, +1.5 points.

Conclusions: The three scales proved adequate for longitudinal assessment of PD disability. UPDRS-ADL was more precise and ISAPD more consistent. Magnitude of change and correlation with change in HY were slightly higher with the ISAPD. Effect size and standardized response mean for the minimal change in HY were higher for the UPDRS-ADL.

Citing Articles

Association of Baseline Depression and Anxiety with Longitudinal Health Outcomes in Parkinson's Disease.

Shi Y, Dobkin R, Weintraub D, Cho H, Caspell-Garcia C, Bock M Mov Disord Clin Pract. 2024; 11(9):1103-1112.

PMID: 39367742 PMC: 11452785. DOI: 10.1002/mdc3.14145.


Bridging the gap between statistical significance and clinical relevance: A systematic review of minimum clinically important difference (MCID) thresholds of scales reported in movement disorders research.

Mishra B, Sudheer P, Rajan R, Agarwal A, Srivastava M, Nilima N Heliyon. 2024; 10(5):e26479.

PMID: 38439837 PMC: 10909673. DOI: 10.1016/j.heliyon.2024.e26479.


Minimal Clinically Important Difference (MCID) in Patient-Reported Outcome Measures for Neurological Conditions: Review of Concept and Methods.

Mishra B, Sudheer P, Agarwal A, Srivastava M, Nilima , Vishnu V Ann Indian Acad Neurol. 2023; 26(4):334-343.

PMID: 37970301 PMC: 10645230. DOI: 10.4103/aian.aian_207_23.


Gait Analysis with Wearables Is a Potential Progression Marker in Parkinson's Disease.

Zhu S, Wu Z, Wang Y, Jiang Y, Gu R, Zhong M Brain Sci. 2022; 12(9).

PMID: 36138949 PMC: 9497215. DOI: 10.3390/brainsci12091213.


Measurement tools to assess activities of daily living in patients with Parkinson's disease: A systematic review.

Bouca-Machado R, Fernandes A, Ranzato C, Beneby D, Nzwalo H, Ferreira J Front Neurosci. 2022; 16:945398.

PMID: 35992900 PMC: 9386643. DOI: 10.3389/fnins.2022.945398.